<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase I:  An Injectable Treatment for the Repair of Damaged Tendons and Ligaments</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>09/15/2020</AwardEffectiveDate>
<AwardExpirationDate>08/31/2021</AwardExpirationDate>
<AwardTotalIntnAmount>255947.00</AwardTotalIntnAmount>
<AwardAmount>255947</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Erik Pierstorff</SignBlockName>
<PO_EMAI>epiersto@nsf.gov</PO_EMAI>
<PO_PHON>7032922165</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop safe and affordable COVID-19 vaccination technology, with broader utility in preventing other types of outbreak in the future. This novel vaccination platform is based on modifying bacteria, long used as a cost-effective, safe vaccine for pediatric tuberculosis immunization. The novel vaccine is anticipated to show heat-stability, safety, cost-effectiveness, and ease of mass production. It may be employed for pediatric immunizations and for other at-risk groups, including first responders, the elderly, and those with underlying chronic conditions. In addition, this can be used in emerging and disadvantaged communities.  &lt;br/&gt;&lt;br/&gt;The proposed project enables a novel microbial vaccine platform based on recombinant BCG bacteria (rBCG) engineered to target SARS-CoV-2, with the potential to protect against COVID-19 disease. This new design addresses the potential limitation of a lack of specificity to SARS-CoV-2. Preliminary results demonstrate that the integration and the expression of foreign genes can be successfully achieved in BCG bacteria. This project will develop BCG that expresses SARS-CoV-2 protein fragments, which could lead to the induction of appropriate immune responses against SARS-CoV-2 specific antigens. New rBCG candidates with the highest secretion and durable expression levels of viral polypeptides will be selected and prioritized based on their biological properties. The rBCG vaccines will be evaluated for safety and immunogenicity in animal models. Promising vaccine candidates that show no adverse events and induce robust T-cell and antibody responses will be selected for future studies.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>09/14/2020</MinAmdLetterDate>
<MaxAmdLetterDate>10/13/2020</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2026007</AwardID>
<Investigator>
<FirstName>Adam</FirstName>
<LastName>Hacking</LastName>
<PI_MID_INIT>S</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Adam S Hacking</PI_FULL_NAME>
<EmailAddress>adam.hacking@regenxus.com</EmailAddress>
<PI_PHON>6179973862</PI_PHON>
<NSF_ID>000749057</NSF_ID>
<StartDate>09/14/2020</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>RegenX LLC</Name>
<CityName>Burlington</CityName>
<CountyName>MIDDLESEX</CountyName>
<ZipCode>018035118</ZipCode>
<PhoneNumber>6179973862</PhoneNumber>
<StreetAddress>145 South Bedford St</StreetAddress>
<StreetAddress2><![CDATA[Rm 125]]></StreetAddress2>
<CountryName>United States</CountryName>
<StateName>Massachusetts</StateName>
<StateCode>MA</StateCode>
<CONGRESSDISTRICT>03</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>MA03</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>080587024</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>REGENX LLC</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[RegenX]]></Name>
<CityName>Lowell</CityName>
<CountyName>MIDDLESEX</CountyName>
<StateCode>MA</StateCode>
<ZipCode>018524574</ZipCode>
<StreetAddress><![CDATA[110 Canal St]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Massachusetts</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>03</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>MA03</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>5371</Code>
<Text>SBIR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>008E</Code>
<Text>Gene and Drug Delivery</Text>
</ProgramReference>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<ProgramReference>
<Code>8038</Code>
<Text>Biotechnology</Text>
</ProgramReference>
<Appropriation>
<Code>0120</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2020~255947</FUND_OBLG>
</Award>
</rootTag>
